A detailed history of Nuveen Asset Management, LLC transactions in X Biotech Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 24,879 shares of XBIT stock, worth $179,377. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,879
Holding current value
$179,377
% of portfolio
0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$4.54 - $9.89 $112,950 - $246,053
24,879 New
24,879 $127,000
Q2 2022

Aug 15, 2022

SELL
$5.13 - $9.2 $453,492 - $813,279
-88,400 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$8.64 - $11.71 $21,064 - $28,548
2,438 Added 2.84%
88,400 $764,000
Q4 2021

Feb 14, 2022

BUY
$10.95 - $16.07 $170,228 - $249,824
15,546 Added 22.08%
85,962 $957,000
Q3 2021

Nov 12, 2021

SELL
$12.95 - $18.24 $457,562 - $644,473
-35,333 Reduced 33.41%
70,416 $912,000
Q2 2021

Aug 16, 2021

BUY
$15.83 - $17.84 $500,607 - $564,172
31,624 Added 42.66%
105,749 $448,000
Q1 2021

May 17, 2021

SELL
$15.92 - $20.3 $134,205 - $171,129
-8,430 Reduced 10.21%
74,125 $1.15 Million
Q4 2020

Feb 16, 2021

BUY
$15.65 - $19.92 $116,749 - $148,603
7,460 Added 9.93%
82,555 $1.29 Million
Q3 2020

Nov 16, 2020

BUY
$13.97 - $21.16 $112,905 - $171,015
8,082 Added 12.06%
75,095 $1.43 Million
Q2 2020

Aug 14, 2020

BUY
$10.39 - $16.07 $58,028 - $89,750
5,585 Added 9.09%
67,013 $918,000
Q1 2020

May 14, 2020

SELL
$8.89 - $24.94 $104,848 - $294,142
-11,794 Reduced 16.11%
61,428 $652,000
Q4 2019

Feb 14, 2020

BUY
$8.33 - $19.95 $129,506 - $310,162
15,547 Added 26.96%
73,222 $1.37 Million
Q3 2019

Nov 14, 2019

BUY
$6.86 - $10.46 $99,017 - $150,979
14,434 Added 33.38%
57,675 $634,000
Q2 2019

Aug 15, 2019

BUY
$6.99 - $11.27 $302,254 - $487,326
43,241 New
43,241 $328,000

Others Institutions Holding XBIT

About XBiotech Inc.


  • Ticker XBIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,439,300
  • Market Cap $219M
  • Description
  • XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...
More about XBIT
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.